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Abstract 
Cardiac troponin I (cTnI) is considered a specific and a sensitive biomarker of cardiac disease, 
and due to a high inter-species sequence homology; human cTnI assays can often be used in 
veterinary medicine. The main aim of this study was to perform an initial evaluation of a human 
cTnI test, the Meritas Troponin I test, for measurement of equine plasma cTnI, in order to 
investigate whether the test could be a possible subject for a more comprehensive validation. The 
hypothesis was that the test could measure equine cTnI, as there is a good homology between 
equine cTnI and human cTnI.  
The evaluation included a dilution parallelism, an intra-assay precision study and measurement 
of plasma cTnI healthy horses. In the dilution parallelism and the intra-assay precision study, 
equine plasma with previously established high cTnI concentration, according to another cTnI 
assay, was used. In addition, cTnI concentration was measured in plasma, collected from 19 
horses, without signs of disease at physical and ECG examinations.  
The obtained curve in the dilution parallelism was linear, indicating that the Meritas Troponin I 
test can be used to measure different concentrations of equine cTnI in plasma. The mean CV% of 
the test was 6.7% when the concentration of cTnI in plasma was above the detection limit of 12 
ng/L. However, the CV% varied extensively when the concentration of cTnI in plasma was < 12 
ng/L. All healthy horses, except for one, had a mean cTnI concentration below or close to the 
detection limit of the test, which is consistent with previous studies. The results indicate that the 
Meritas Troponin I test may be used to measure equine cTnI, and may have a potential use in 
equine medicine. However, in order to determine its clinical value in horses, a more 
comprehensive validation is required. 
Sammanfattning 
Hjärtspecifikt troponin I (cTnI) anses vara en specifik och en känslig biomarkör för 
hjärtsjukdom. Aminosyrasekvensen mellan arter är väl konserverad vilket innebär att humana 
cTnI assays ofta kan användas inom veterinärmedicinen. Huvudsyftet med denna studie var att 
göra en initial utvärdering av ett human-baserat cTnI-test, Meritas Troponin I test, och undersöka 
om det skulle kunna mäta ekvint cTnI i plasma. Utvärderingen utfördes för att undersöka om 
testet skulle kunna bli föremål för en mer omfattande validering. Hypotesen var att ekvint cTnI i 
plasma kunde mätas med Meritas Troponin I test då homologin är god mellan humant och ekvint 
cTnI.  
I utvärderingen ingick utförande av en spädningsserie, kontroll av testets exakthet samt mätning 
av plasma cTnI hos friska hästar. I spädningsserien och utvärderingen av testets exakthet 
användes ekvin plasma, tidigare analyserat med en annan cTnI-assay, med förhöjt cTnI-värde. I 
denna studie mättes också koncentration av cTnI i plasma hos 19 stycken hästar, som vid klinisk 
undersökning och EKG inte uppvisade tecken på sjukdom. 
I spädningsserien erhölls en rätlinjig spädningskurva vilket indikerar att ekvint cTnI i olika 
koncentrationer kan mätas med Meritas Troponin I test. Vid plasmakoncentrationer över testets 
detektionsgräns (12 ng/l) låg CV-värdet på 6,7 % och vid plasmakoncentrationer < 12 ng/l 
varierade CV-värdet mycket. Alla friska hästar, utom en, hade en medelkoncentration av cTnI i 
plasma som låg nära eller under detektionsgränsen för testet vilket stämmer överens med tidigare 
utförda studier. Resultaten från denna studie indikerar att Meritas Troponin I test kan användas 
för att mäta ekvint cTnI och att testet eventuellt skulle kunna användas kliniskt inom 
hästmedicinen. Innan detta kan ske krävs dock en mer omfattande validering av denna metod. 
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INTRODUCTION  
Myocardial disease 
Disorders that primarily affect the myocardium by causing necrosis, degeneration or 
inflammation are called “myocardial diseases”, which can be classified as either primary or 
secondary myocardial diseases (Mattingly 1965, Van Vleet & Ferrans 1986). Diseases that 
primary involve the myocardium, with none or little involvement of other structures of the heart, 
are referred to as primary myocardial diseases (Mattingly 1965). Fowler and Gueron (1965) 
defined primary myocardial disease in humans as “a variety of cardiac enlargement which is of 
unknown cause and frequently leads to cardiac dilatation, congestive heart failure and finally to 
death”. The term “secondary myocardial disease” refers to diseases which, while not primarily 
affecting the myocardium, do cause secondary pathological changes in the myocardium 
(Mattingly 1965). 
In horses, there is a variety of pathophysiological mechanisms behind myocardial diseases e.g. 
infection and trauma, and myocardial diseases are likely to be under-diagnosed (Reed, Bayley & 
Sellon 2010, p. 447). Clinical signs of myocardial disease are exercise intolerance, ataxia, 
sudden death, and reduced performance (Reed, Bayley & Sellon 2010, p. 448). 
In case of myocardial injury, an intracellular regulatory protein called cardiac troponin, may leak 
out from injured myocytes out into the circulation (Hein, Scheffold & Schaper 1995, Bleier et al. 
1998, Buergelt et al. 2003, Fishbein et al. 2003, Wilson et al. 2009). Troponin can therefore be 
measured to detect myocardial damage. 
Troponin 
Troponin is part of the muscle troponin-tropomyosin complex and consists of three proteins, 
troponin C (TnC), troponin I (TnI) and troponin T (TnT) (Greaser & Gergely 1971, Katz 2011). 
Together with tropomyosin, troponin forms a complex which is part of the thin filaments in the 
myofibrils present in skeletal muscle and in cardiac muscle. The troponin complex is involved in 
the calcium-dependent regulation of muscle contraction. (Ebashi, Kodama & Ebashi 1968, Katz 
2011). Each of the three troponin proteins exists in tissue specific isoforms, in cardiac muscle 
and in skeletal muscle respectively (Syska, Perry & Trayer 1974, Dhoot, Gell & Perry 1978, 
Dhoot & Perry 1979, Dhoot & Perry 1980, Wilkinson 1980, Schreier, Kedes & Gahlman 1990, 
Pan & Potter 1992, Anderson et al. 1995).  
There are three isoforms of cTnI, one for cardiac muscle, one for fast skeletal muscle fibers and 
one for slow skeletal muscle fibers (Dhoot, Gell & Perry 1978). Cardiac troponin I (cTnI) is 
considered cardio-specific since the level of cTnI is 1000 times higher in cardiac myocytes, 
compared to the level in skeletal muscle fibers, and in commercial tests 0.05 - 0.1% of skeletal 
muscle troponin cross reacts with cTnI (Mair et al. 1996, O’Brien, Landt & Ladenson 1997). In 
human medicine, cTnI has become the clinically most important of the isoforms due to its 
cardio-specificity, and also because it has the longest half-life in plasma (Bodor et al. 1992, 
Hjortshøj et al. 2008). 
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Cardiac troponin is located intracellularly, where approximately 8% of the total amount of 
troponin in the myocardium is unbound in the cytoplasm (Bleier et al. 1998). In case of 
myocardial injury, caused by ischemia or necrosis, the permeability of the cell membrane of the 
myocytes is altered, which causes troponin to leak out from the myocytes into the circulation 
(Hein, Scheffold & Schaper 1995, Buerguelt 2003, Fishbein et al. 2003, Wilson et al. 2009).  
Cardiac troponin I in humans 
Cardiac troponin I (cTnI) is one of the most studied biomarkers of cardiac disease in human 
medicine, and has proven to be a sensitive and a specific biomarker of cardiac disease (Adams et 
al. 1994a, Adams et al. 1994b, Jaffe et al. 1996, Mair et al. 1996). The increase of cTnI in plasma 
can be correlated to the size of myocardial infarction (Mair et al. 1995).  
Cummins, Auckland & Cummins (1987) reported the first human cTnI assay, which had a lower 
limit of detection of 10,000 ng/L and had a cross reactivity of 2 % with skeletal muscle TnI. 
Since then, second and third generations human cTnI assays with higher sensitivity and lower 
limit of detection, have been developed (Panteghini et al. 2004, Venge et al. 2008, Wilson 2009). 
For example, the Nanosphere assay can measure cTnI concentrations in plasma down to 0.2 ng/L 
(Wilson et al. 2009).  
Cardiac Troponin I in horses 
In 1997, O’Brien, Landt & Ladenson confirmed the presence of cTnI in the equine myocardium 
and studies have shown that cTnI is a specific and a sensitive marker of myocardial injury in 
horses (O’Brien et al. 1997, Divers et al. 2009, Kraus et al. 2010). The sequence homology for 
cTnI across species is > 90 % (equine 89.1%1) and therefore human cTnI assays may be used for 
measurement of cTnI concentration in plasma in other species including horses (Rishniw & 
Simpson 2005). Most second and third generations human cTnI assays have antibodies targeted 
against epitopes of the cTnI molecule that are highly conserved between species (Rishniw & 
Simpson 2005). Therefore, these assays can often be used across species to measure cTnI 
(Rishniw & Simpson 2005). However, it is recommended to validate the assay, for the desired 
species, before using the assay in veterinary practice in order to control its specificity and 
sensitivity (Serra et al. 2010).  
In horses without clinical signs of disease, plasma cTnI concentrations are often very low, and 
the concentration of cTnI does not seem to be influenced by age, sex or breed in horses (Phillips 
et al. 2003, Begg & Begg 2006, Kraus et al. 2010). However, no comprehensive study has been 
made to determine plasma cTnI concentrations in healthy horses, and therefore it is uncertain 
which factors influence the concentration. In horses with myocardial damage, plasma cTnI 
concentration is often increased (Schwarzwald et al. 2003, Kraus et al. 2010, Decloedt et al. 
2012, Nath et al. 2012b). Myocardial damage/necrosis has been seen in horses with monensin 
toxicosis, and lasalocid poisoning, together with increased cTnI concentrations in plasma, 
indicating that increased cTnI concentration in plasma is associated with myocardial injury in 
horses (Divers et al. 2009, Kraus et al, 2010, Decloedt et. al. 2012).  
1 Uniprot. (2014-01-26). Alignment. http://www.uniprot.org/align/201401262BIDE1ZHUM [2014-01-26]. 
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Increased plasma cTnI concentrations have been reported in horses with experimentally induced 
endotoxaemia, nutritional masseter myodegeneration, myocardial disease, rattlesnake 
envenomation, horses with colic, in some horses after transvenous electrical cardioversion, 
rhabdomyolysis secondary to Anaplasma infection, atypical myopathy, in septic neonatal foals, 
after strenuous exercise and in some horses after race (Slack et al. 2005, Holbrook et al. 2006, 
Hilton, Madigan & Aleman 2008, Nostell & Häggström 2008, Divers et al. 2009, Jesty et al. 
2009, Schefer et al. 2011, Gilliam et al. 2012, Nath et al. 2012a, Nath et al. 2012b, Nostell et. al. 
2012, Radcliff et al. 2012, Verheyen et. al. 2012). 
The half-life of equine cTnI in plasma is 0.47 h. However, elevated concentrations of plasma 
cTnI have been reported in horses for a prolonged period of time (14 days) (Kraus et al. 2012, 
Nath et al. 2012b). This is likely related to a continuous release of cTnI from the myocardium 
caused by an ongoing myocardial injury (Nath et al. 2012b). Increased cTnI-concentrations in 
plasma can be observed four hours after infusion of endotoxin using a high sensitivity cTnI assay 
(Nostell et al. 2012). After intragastric administration of sodium monensin, increased plasma 
cTnI concentration was observed after 24 – 72 hours (Divers et al. 2009). 
Various assays have been used in different studies for determination of cTnI concentration in 
equine plasma, but few of the assays have been validated. In 2006, Begg & Begg validated the 
ADVIA Centaur assay from Bayer, and found that it could detect equine cTnI. Kraus et al. 
(2010) validated a bedside assay, and found that the obtained cTnI concentrations in equine 
plasma, using the bedside assay, were similar to the concentrations obtained when using a bench-
top analyzer. Slack et al. (2012) performed a validation of the Stratus CS immunoassay and 
determined the 95th and 99th percentile upper reference limits for healthy Standardbred horses. 
The advantage of a beside test is that the clinician will obtain a result faster, and thus be able to 
decide and choose further diagnostics or treatment when presented to a horse with a suspected 
myocardial injury. In addition, the samples can be run immediately after collection which may 
give a more accurate value as the concentration of cTnI may decrease rapidly in room 
temperature. In dogs and humans cTnI concentrations in plasma decrease to various extent in 
room temperature (Venge, Lindahl & Wallentin 2001, Oyama & Solter 2004, Slack et al. 2012). 
However, no study of the stability of cTnI in equine plasma stored in room temperature has been 
made. There is also an economic aspect of having a bedside test because assaying the samples 
with a bedside test is often cheaper than sending the samples to a reference laboratory.  
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Aims of the study 
Evaluation of the Meritas Troponin I test 
The main aim of the study was to perform an initial evaluation of the human cTnI test, Meritas 
Troponin I test, manufactured by Trinity Biotech, for measurement of equine cTnI in plasma. 
The initial evaluation in the present study included a dilution parallelism, investigation of the 
intra-assay precision and measurement of plasma cTnI in healthy horses. This initial evaluation 
was performed in order to determine if the test could be subject for a further, more 
comprehensive validation. The hypothesis was that the test could measure equine cTnI as there is 
a good homology between equine and human cTnI. 
Previous studies have shown that plasma cTnI concentrations in healthy horses are low, often 
near or below the detection limit of the assay.  In the present study, it was hypothesized that the 
healthy horses would have low plasma cTnI concentrations, or concentrations below the 
detection limit of the Meritas Troponin I test.  
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MATERIALS AND METHODS  
The present study was performed at the Swedish University of Agricultural Studies (SLU) in 
Uppsala, Sweden. Blood samples were collected from horses at a riding school in Uppsala, and 
at the Department of Clinical Sciences at the Swedish University of Agricultural Sciences in 
Uppsala. The study was sanctioned by the Ethical Committee for Animal Experiments, Uppsala, 
Sweden. 
Assay2 
The Meritas Troponin I test is used with the Meritas POC analyzer, a quantitative lateral flow 
immunoassay that uses fluorescence-based measurement for detection of cTnI. The assay is 
developed for human use, and can measure various biomarkers by using different analyse 
cartridges/tests. In the present study, the cartridge for measurement of cTnI was used, Meritas 
Troponin I test. The assay is manufactured by Trinity Biotech, and Fiomi Diagnostics 
manufactures the cartridges.  
The test uses detection antibodies directed towards human epitope 24 – 40, 137 – 148 and 190 – 
196 and capture antibodies directed against epitope 41 – 49 and 87 – 91. The epitopes are 
homologous between humans and horses except for human epitope 91 where human cTnI has an 
alanine and equine cTnI has a glutamic acid. 
Whole blood, lithium heparin and EDTA plasma can be used for measurement of human cTnI 
with the Meritas POC analyzer. However, the manufacturer recommends EDTA-plasma for 
measurement of cTnI in human plasma. In the present study only lithium heparin plasma was 
used. The defined measuring range of the test is 12 – 30,000 ng/l for human EDTA plasma.3 The 
amount of sample required per run is 200 µl. 
Experimental Design 
Evaluation of the Meritas Troponin I test 
The total volume of each sample analysed was 200 µl, as stated in the guidelines from the 
manufacturer. 
Dilution parallelism 
A lithium heparin plasma sample collected from a horse previously treated at the Animal 
Hospital at SLU, with known cardiac injury and high concentrations of cTnI in plasma4 was used 
for the dilution parallelism study. The sample had been stored at –80 ° C, and had not been 
thawed before the start of the present study. The plasma sample was diluted with lithium heparin 
plasma collected from two healthy Standardbred trotters, owned by the Department of Clinical 
2 As stated in the Meritas POC analyzer operation manual. 
3 According to the IFU provided by the manufacturer. 
4 Sample had been analysed at Akademiska Sjukhuset in Uppsala, Sweden, where the cTnI concentration had been 
measured by Beckman-Coulter assay. 
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Sciences at the Swedish University of Agricultural Sciences, with known low concentrations of 
plasma cTnI (< 2 ng/L5).  
Due to low sample volume, the plasma with high cTnI concentration was first diluted 1:5 with 
the plasma mentioned above. Before the start of the dilution parallelism, the initial diluted 
sample was analysed in triplicate. Dilution of the plasma with high concentration of cTnI was 
made in the following steps: 4:1, 3:2, 2:3, 1:4, 1:9, 1:19 and 1:99. All diluted samples were 
analysed in duplicates. 
Intra-assay precision 
The intra-assay precision was calculated using the obtained values in the dilution parallelism. To 
further investigate the intra-assay precision, another plasma sample from the horse with 
previously established high cTnI concentration, was diluted with equine lithium heparin plasma 
with known low cTnI concentration (< 2 ng/L), in the following steps: 4:1, 3:2, 2:3, 1:4 and 1:9. 
The samples were run in duplicates. 
Samples from healthy horses 
19 horses, four fillies and 15 geldings, with a mean age of 11.5 years (range 6 – 19 years) were 
included in the study. The horses consisted of 17 Warmbloods (seven German Warmbloods, five 
Polish Warmbloods, three Dutch Warmbloods, one Irish Warmblood and one Swedish 
Warmblood), one English Thoroughbred and one American Paint horse. Three of the horses 
were privately owned whereas the rest of the horses belonged to a riding school located in 
Uppsala, Sweden. All horses underwent a standard clinical examination, including a thorough 
auscultation of the heart as well as a one-minute ECG recording, in order to check for signs of 
arrhythmia. The ECG recording was obtained using an Alive Cor Vet for iPhone 4S. None of the 
horses showed any significant findings on clinical examination or on the ECG recordings. Based 
on the examination, none of the horses showed signs of cardiovascular disease, or other disease.  
Blood sample collection  
Venous blood samples were collected in 4 ml lithium heparin tubes6 from one of the jugular 
veins, using Vacutainer technique7. All samples were collected at rest with the horse standing 
calmly in the box stall. After collection, the samples were stored on ice, and transported to the 
Swedish University of Agricultural Sciences where the samples were centrifuged at 3000 rpm 
during 10 minutes using the Hettich EBA 20 centrifuge. All samples were centrifuged and stored 
at – 80 ° C within four hours after collection. The samples were thawed at room temperature 30 
minutes prior to analysis with the Meritas POC analyzer. In the dilution parallelism, the samples 
were kept on ice at 4 ° C after being diluted, and then thawed until they reached room 
temperature before they were assayed. In the intra-assay precision study, the samples were kept 
on ice after being diluted, and then thawed until they reached room temperature before they were 
assayed. 
5 Samples were sent to Akademiska Sjukhuset in Uppsala, Sweden, where determination of cTnI concentration was 
made using Abbott Architect cTnI assay. 
6 BD vacutainer Li-Hep, Belliver Industrial Estate, Plymouth, UK. 
7 BD Vacutainer precision glide 0.9 x 38 mm, Belliver Industrial Estate, Plymouth, UK. 
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Statistical analysis 
All values are expressed as mean ± standard deviation (SD). The intra-assay precision, defined 
as the variation between measured cTnI concentrations of plasma samples from the same horse 
or samples in the same dilution step, run in two or three consecutive runs, was expressed as 
coefficient of variation in percentage (CV%8). The expected value in the dilution parallelism was 
calculated by using the mean concentration of the undiluted sample with known high cTnI 
concentration. The linearity of the dilution parallelism was determined via t-based, ordinary 
Least Squares regression analysis with a 95 % confidence interval, using Analyse-it Method 
Validation software Version 3.70.1 and Microsoft Excel 2013.   
8 The CV% was calculated by dividing SD by the mean of two or three aliquots multiplied by 100 
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RESULTS 
Evaluation the Meritas Troponin I Test 
Dilution parallelism 
A triplicate of the plasma sample with previously established high concentration of cTnI was run 
where the measured concentration was 327 ng/L in the first run, 305 ng/L in the second run and 
288 ng/L in the third run9. The average concentration of the undiluted sample was 306 ng/L.  
Figure 1.Dilution parallelism with results of measurement 1 (Aliquot 1), measurement 2 (Aliquot 
2), mean concentration and expected concentration.  
 
 
 
 
 
 
9 Data from the third run is not included in table 1. 
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Table 1. Measured concentrations in the dilution parallelism 
Dilution  Measured 
concentration 
(ng/L) 1 
Measured 
concentration 
(ng/L) 2 
Mean 
concentration 
(ng/L) 
Expected 
value  
(ng/L) 
Measured/ 
expected 
value 
(ng/L) 
Standard 
deviation 
CV % 
1:0 327 305 306 306 1.0 19.5 6 
4:1 278 306 292 245 1.2 19.8 6.8 
3:2 209 226 217 184 1.2 12.0 5.5 
2:3 183 163 173 123 1.4 14.1 8.1 
1:4 114 108 111 61 1.8 4.2 3.8 
1:9 49 59 54 31 1.8 7.1 13.1 
1:19 7 6 6.5 15 0.4 0.7 10.9 
1:99 < 1 3 2 3 0.3 1.4 70.7 
 
In the regression analysis, using a 95 % confidence interval, the curve of the obtained 
concentrations demonstrated a linear curve parallel with the curve of the expected concentration 
where the slope of the lines ranged from 0.77 to 1.23 (SD 0.09). The intercept was 28.6 ng/L and 
when using a 95 % confidence interval, ranged from -10 to 67.8 ng/L (SD 15.13) (figure 2). The 
correlation coefficient was 0.981. 
Figure 2. Plot of the obtained verses the expected concentrations for cTnI. 
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Intra-assay precision study  
Measured concentrations below 12 ng/L were not included in the intra-assay precision study 
since 12 ng/L is the limit of detection of the Meritas Troponin I test, and therefore CV% is 
expected to vary. 
In the dilution parallelism the CV% ranged from 3.8 – 13.1 (mean 7.2 ± SD 2.9). After 
exclusion of the highest and lowest values, the CV% ranged from 5.5 – 8.1 (mean 6.6 ± SD 
0.98). In addition to the obtained CV% in the dilution parallelism, intra-assay precision was 
further investigated by diluting another plasma sample, collected from the same horse used in the 
dilution parallelism study. The CV% ranged from < 0.1 – 11.0 (mean 6.7 ± SD 3.8). When 
highest and lowest values were excluded, CV% ranged from 4.9 – 10.2 (mean 7.1 ± SD 2.4). 
(Table 2). 
The mean CV%, when combining the results mentioned above, was 6.8 (range < 0.1 – 13.1) ± 
SD 3.3. When the lowest and the highest values were excluded, CV% ranged from 3.8 – 11.0, 
and mean CV% was 6.9 ± SD 2.2. 
Table 2. Measured and mean concentrations, standard deviation and CV% obtained from a 
diluted plasma sample from a horse with previously established high cTnI concentration. 
Dilution  Measured 
concentration 
(ng/L) 1 
Measured 
concentration 
(ng/L) 2 
Mean 
concentration 
(ng/L) 
Standard 
deviation 
CV % 
1:0 1377 1277 1327 70.7 5.3 
4:1 444 519 482 53.0 11.0 
3:2 556 498 527 41.0 7.8 
2:3 396 369 283 19.1 4.9 
1:4 274 237 256 26.1 10.2 
1:9 85 84 84.5 0.7 < 0.1  
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Plasma cTnI concentration in healthy horses 
Three horses (horse 4, 7, 19) were excluded from the study as the test was not able to quantify 
the concentration of cTnI in the samples. All other horses had cTnI concentrations below or near 
the detection limit of the test. In five of the horses, CV% was > 37.2, and in the remaining horses 
the CV% was < 20.2. (Table 3). Horse 10 was the only horse that had plasma cTnI concentration 
above the detection limit of the test, and there the CV% was 12.9. 
Table 3. Equine cTnI concentration in plasma in healthy horses. 
Horse Measured 
concentration 
1 (ng/L) 
Measured 
concentration 
2 (ng/L) 
Standard 
deviation
10 
Mean11 
(ng/L) 
CV % 
Horse 1 1 < 1 0 1 0 
Horse 2 2 7 3.5 4.5 78.6 
Horse 3 1 < 1 0 1 0 
Horse 5 10 10 0 10 0 
Horse 6 < 1  < 1 0 1  0 
Horse 8 < 1 < 1 0 1 0 
Horse 9 < 1 < 1 0 1 0 
Horse 10 15 18 2.1 16.5 12.9 
Horse 11 1  7 4.2 4 106.1 
Horse 12 6 8 1.4 7 20.2 
Horse 13 12 7 3.5 9.5 37.2 
Horse 14 < 1 8 4.9 4.5 110 
Horse 15 3 4 0.7 3.5 20.2 
Horse 16 < 1 6 3.5 3.5 100  
Horse 17 < 1 < 1 0 1 0 
Horse 18 < 1 < 1  0 1 0 
10 In the calculations all values < 1 were calculated as 1. 
11 In the calculations all values < 1 were calculated as 1. 
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DISCUSSION  
The present study indicates that the Meritas POC analyzer may have the capability to measure 
equine cTnI and, accordingly, could the analyzer be a candidate for further validations. In the 
intra-assay precision study, the test had a mean CV% of 6.7 (range < 0.1 – 13.1) for samples 
with cTnI concentration > 12 ng/L. However, in the blood samples with cTnI concentrations < 
12 ng/L, CV% varied extensively, which is an expected result due to the fact that CV% can vary 
a great deal in samples with concentrations below the limit of detection of an assay/test. 
Therefore, cTnI concentrations in equine plasma < 12 ng/L should be interpreted with care, due 
to the fact that CV% can vary. To further evaluate the Meritas POC analyzer a more 
comprehensive validation should be performed to investigate if the test may be used clinically in 
equine medicine. 
All obtained cTnI-concentrations in the dilution parallelism were higher than the expected, 
calculated concentrations, except for the 1:20 and 1:99 dilutions. This could indicate that 
measured equine plasma cTnI concentrations may be false high in samples with a cTnI 
concentration exceeding the limit of detection. Nonetheless, the concentrations could have been 
higher due to matrix-effects, which can be seen when plasmas from different individuals are 
mixed.  
Only one of the epitopes, epitope 91, targeted by the Meritas Troponin I test differed between 
human cTnI and equine cTnI. The human epitope 91 is an alanine, whereas the equine 
corresponding epitope is a glutamic acid. Alanine is non-polar and hydrophilic whereas glutamic 
acid is negatively charged which may affect the three dimensional structure of the protein, thus 
alter the binding capacity of the antibodies used in the Meritas Troponin I test. An altered 
binding capacity may affect the result of the analysis in equine plasma samples since the Meritas 
Troponin I test is produced for human use, thus optimized and standardized for human plasma. 
To investigate the measurement accuracy; a sample with a known concentration of cTnI could be 
measured and then the obtained value could be compared with the known value e.g. by doing a 
spike recovery.  
In the dilution parallelism and the intra-assay precision study, a majority of the first analysed 
samples (64%, 9/14) had higher concentrations than the following samples in the 
duplicate/triplicate series. In horses, no study investigating the stability of equine plasma stored 
at room temperature has been made (Kraus et al. 2012). Human and canine plasma cTnI samples 
are known to be unstable in room temperature. In room temperature, the cTnI concentration 
decreases approximately 10% after 24 h, 50% after 48 h and 70% after 72 h, in canine plasma, 
and 20% after 72 hours in human plasma (Venge, Lindahl & Wallentin 2001, Oyama & Solter 
2004). As the cTnI has a short half-life in plasma in the body, it is likely that equine cTnI also is 
unstable at room temperature. Therefore, there is a possibility that the measured concentrations 
in the first assayed samples were higher, than in the following samples, due to the fact that cTnI 
in equine plasma is unstable at room temperature. However, due to the possible instability of 
equine plasma cTnI at room temperature, the samples in the present study were kept on ice 
and/or at 4 ° C. In addition, the maximal time between the analyses in each duplicate/triplicate 
was 20 minutes. 
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In the present study, the mean CV% in the intra-assay precision study was 6.7%. In human 
cardiology, the recommended CV of cTnI assays is up to 10% at the decision limit, where the 
decision limit is defined as a value that exceeds the 99th percentile of a reference control group 
(Antman et al. 2000). The cut off value for human cTnI is defined as “maximal concentration of 
cardiac troponin exceeding the 99th percentile of values (with optimal precision defined by total 
CV 10%) for a reference control group on at least one occasion during the first 24 h after the 
clinical event…”.12 In horses, assay-specific 99th percentile upper reference limits can be 
determined (Slack et al. 2012). However, there is no defined cut off value for plasma cTnI 
concentrations in horses and therefore a recommended CV% cannot be defined. Therefore it is 
difficult to determine if the CV% is acceptable or not.  
The healthy horses in the present study all had mean cTnI concentrations below or close to the 
limit of detection. Previous studies in clinically healthy horses have shown that they generally 
have low cTnI concentrations (below or close to the detection limit of the assay) with reported 
concentrations of  0 – 350 ng/L, depending on the assay used (Phillips et al. 2003, Begg, 
Hoffmann & Begg 2006, Nostell et al. 2008, Kraus et al. 2010, Slack et al. 2012). Thus, the 
result obtained in this study is in agreement with results from previous studies. 
There are several examples of scenarios where access to a bedside test for measurement of cTnI 
is desirable. An example of a scenario where a quick cTnI result is desirable would be in the case 
of colic. In colic horses admitted for surgery an elevated cTnI value is associated severity of 
disease, poorer prognosis, and the horse is less likely to survive. 9/25 horses with strangulating 
obstruction and 9/19 with inflammatory disease, had cTnI values up to 9310 ng/L. (Nath et al. 
2012a). In a study by Radcliffe et al. (2012) non-surviving colic horses had several fold higher 
mean preoperative cTnI value than the surviving horses. Thus, a higher concentration of plasma 
cTnI was associated with poorer prognosis, indicating that analysis of cTnI concentration in 
horses with colic may be of prognostic value. The cTnI concentration can be part of the clinical 
examination when considering admitting a colic horse for laparotomy. However, a decision 
whether a horse should undergo laparotomy or not should not be based on a single blood 
variable, but rather as one of several clinical variables used for decision making. Another clinical 
setting where cTnI may have a clinical value is in myopathies. Increased cTnI concentrations are 
an indication of myocytes damage and repeated measurements will give the veterinarian 
information about the course of the myocardial damage. If the cTnI values remain elevated the 
horse has an ongoing myocytolysis and exercise should be avoided (Jesty et al. 2009). By doing 
follow ups on the cTnI value, together with clinical examination and other diagnostic methods 
the veterinarian can decide when the owners can start exercising the horse again. 
 
 
  
12 Laboratory Medicine guidelines for biomarkers of acute coronary syndromes and heart failure issued by the 
National Academy of Clinical Biochemistry in 2007. 
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Study limitations 
Handling of the samples could have influenced the results in the study. The time between the 
duplicate/triplicate runs could have influenced the result, where a longer time would result in a 
lower second measured concentration. Thus, affecting both the result of the dilution parallelism 
and the intra-assay precision study.  
In the present study, the highest cTnI concentration measured was 1377 ng/L, whereas the 
measuring range of the Meritas Troponin I test is 12 – 30,000 ng/L. Therefore, it would have 
been interesting to use a plasma sample with a higher concentration in the dilution parallelism, 
but also in the intra-assay precision study. Another factor that could have influenced the results 
is the dilution of the samples. In order to perform an accurate dilution, calibrated pipettes were 
used. 
None of the samples were run immediately after collection in the study due to practical reasons. 
This differs from clinical practice where the samples are mostly run after collection, without 
being frozen.  
This study should be considered as an initial evaluation of the Meritas Troponin I test. In order to 
investigate the clinical potential of the Meritas Troponin I test in equine medicine, a 
comprehensive validation is required.  
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CONCLUSIONS  
In the present study an initial evaluation of the Meritas Troponin I test was made, where the 
dilution parallelism demonstrated a linearity indicating different concentrations of equine cTnI in 
lithium-heparin plasma may be measured using Meritas Troponin I test. The mean CV% in the 
intra-assay precision study was 6.7% in samples with cTnI concentrations > 15 ng/L. The test 
tended to give higher concentrations than expected, which means that there is a risk of getting 
false high results. The intra-assay precision study and the dilution parallelism indicated that 
measured cTnI concentrations in equine plasma below 15 ng/L should be interpreted with care. 
All healthy horses had low concentrations of cTnI in plasma, a result consistent with previous 
studies in horses.  
In conclusion, having a bedside test is beneficial for both the patient, the animal owner and the 
veterinarian. In clinical practice, measurement of cTnI is useful when the patient has a suspected 
myocardial damage. The Meritas Troponin I test demonstrated, in the present study, an 
acceptable curve in the dilution parallelism, a CV% below 10%, and plasma cTnI concentrations 
in healthy horses close to or below the limit of detection. This makes the test a possible 
candidate for a future validation in order to properly investigate its possible clinical value in 
equine medicine. 
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